GLP-1s for PCOS: promising signal or overhyped shortcut?

What did @haileyandreasen actually say?

She shared a personal update: after a year on a GLP-1 medication, her doctor told her she "no longer meets the criteria for PCOS." She listed the symptoms she had before, including irregular periods, insulin resistance, and fatigue, and said her hormones "were finally stabilized" after starting the medication. She credits lifestyle changes too, but frames the GLP-1 as the reset that made the difference. She also links to her telehealth provider in her bio, which means this is partly a referral.

To her credit, she does not call it magic or a cure. She explicitly says she made lifestyle changes alongside the medication. That distinction matters, and she deserves credit for saying it out loud instead of burying it.

Does the science back this up?

Partially, yes. GLP-1 receptor agonists do show real benefit for women with PCOS, particularly those whose condition is driven by insulin resistance and excess weight. But "no longer meets criteria for PCOS" is a much stronger statement than anything in the clinical literature right now.

A 2023 meta-analysis by Khattab et al. in Frontiers in Endocrinology found that semaglutide and liraglutide improved menstrual regularity, reduced androgen levels, and improved insulin sensitivity in women with PCOS. A 2022 randomized controlled trial by Jensterle et al. in Obesity found liraglutide outperformed metformin on weight loss and ovulation frequency in PCOS patients. These are meaningful results. They are not the same as remission or a cure.

PCOS is a diagnosis based on the Rotterdam criteria, which requires two of three features: irregular ovulation, elevated androgens, and polycystic ovaries on ultrasound. Weight loss, whether from a GLP-1 or any other intervention, can normalize periods and reduce androgen levels enough that someone no longer meets the diagnostic threshold. That is a real and clinically meaningful outcome. It is not proof the underlying condition is gone.

What did they get wrong (or right)?

She got the mechanism roughly right. Insulin resistance is a major driver of PCOS in a significant subset of patients, and GLP-1 drugs address that directly. The weight loss and improved insulin sensitivity are plausible pathways to the hormonal changes she describes.

What she oversimplifies is what "no longer meeting criteria" actually means. PCOS does not have a clean off switch. A 2020 review by Louwers and Laven in Nature Reviews Endocrinology notes that the condition involves genetic and metabolic factors that persist even when symptoms are controlled. If she regains weight or stops the medication, symptoms can return. Her doctor's statement, as she relays it, sounds like symptom control, not disease resolution. That is an important distinction she does not make.

The bio link to a provider is also worth flagging. This video functions as referral content. That does not make it wrong, but viewers should know the context.

What should you actually know?

GLP-1 medications are not FDA-approved for PCOS. Prescribing them for that indication is off-label, which is legal and sometimes well-supported by evidence, but it means less regulatory oversight of the claim. If you have PCOS and insulin resistance, there is legitimate research suggesting these drugs can help. That conversation belongs with a doctor who reviews your full history, not a TikTok comment section.

The framing of "no longer meeting criteria" is easy to misread as a permanent cure. It is not. PCOS management is ongoing. The Rotterdam criteria are a diagnostic tool, and crossing back below the threshold while on medication does not mean the condition has resolved permanently. Women pursuing this path should understand they may need continued treatment and monitoring, and that results vary significantly based on PCOS subtype and individual metabolic profile.

If you are considering a GLP-1 for PCOS specifically, ask your provider about your androgen levels, your insulin markers, and whether your presentation is the type most likely to respond. Not every PCOS phenotype has the same insulin resistance component, and the evidence is strongest for women whose PCOS is metabolically driven.